FarmPharma receives funding from Vinnova

Report this content

FarmPharma AB that is subsidiary to Double Bond Pharmaceutical Int. AB, has been funded with the amount of SEK 400,000 from Vinnova within the project ”BioProcess Innovation Center” to perform a project in collaboration with GE Healthcare and Testa Center in Uppsala. The total budget of the project is 800 000 SEK and the company will cover the other half of the costs according to the general rules of the grant. The project is expected to start during the summer this year and last for three weeks. The purpose of the project is to test the manufacturing procedure of InterferOX components on a larger scale to facilitate the successful transition to industrial GMP manufacturing of the product.

"It is so crucial for us to get financial support for this project that is expected to be a step forward towards our first GMP batch," - comments Iulia Karlsson, CEO of FarmPharma. - These funds enable us to start a collaboration with GE Healthcare already this spring and take part of their expert knowledge, which we see as an important milestone in the company's development. ”

More about Testa Center:

More about InterferOX:

This information is information that Double Bond Pharmaceutical International AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 25 of April 2019.

Full Company Name:  Double Bond Pharmaceutical International AB (publ)
Corporate identity:     556991-6082
Stock short name:      DBP B
Share ISIN code:         SE0007185525 

For more info, contact
Igor Lokot, CEO




Follow us on LinkedIn, Facebook and Twitter!

Information on Double Bond Pharmaceutical International AB

DBP is a pharmaceutical company with the primary focus on development of therapies against cancer based on the company’s own developed drug delivery technology BeloGal®. The company was granted Orphan Drug Designation status by European Medicines Agency (EMA) in June 2015 for its first product, SA-033, for treatment of hepatoblastoma. Double Bond Pharmaceutical acquired rights to Temodex, a drug registered in Belarus for treatment of brain tumours, in October 2015, and was granted Orphan Drug Designation status by EMA for in July 2016 for this formulation of temozolomide for the treatment of glioma. The formulation is now being further developed for registration in EU and globally and has a working name SI-053 in DBP pipeline. DBP has during the past year also started two subsidiaries, Drugsson AB for the distribution of fully developed human pharmaceutical and medical device products and dietary supplements in Scandinavia, and FarmPharma AB for the development of innovative veterinary products.



Documents & Links